MBrace Therapeutics

MBrace Therapeutics is a clinical-stage oncology company building antibody-drug conjugates (ADCs) against hard-to-drug cancer targets. Its proprietary SPARTA platform screens antibodies directly inside living tumors to surface antigens that are cancer-specific, accessible, and internalizing - the traits an ADC needs to deliver its toxic payload where it counts. Founded in 2020 and headquartered in San Diego, the company raised an $85M Series B in 2023 (led by TPG) to advance a pipeline led by MBRC-101, a first-in-class ADC targeting the EphA5 receptor now in Phase 1/2 clinical trials.